Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity

Bibliography

• Romagnani S. Immunological tolerance and autoimmunity. Intern Emerg Med 2006;1(3):187-96
   PubMed Web of Science ®Google Scholar
• Autoimmune treatment (2009-2014). Available from: www.reportlinker.com/p0148004/Autoimmune-Treatment.html?v=2 [Last accessed 02 July 2010]
   Google Scholar
• Gabriel S, Crowson CS, Maradit Kremers H, Therneau TM. The rising incidence of rheumatoid arthritis [abstract 773]. ACR 24 – 29 October 2008; San Francisco, CA
   Google Scholar
• AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product – Fostamatinib Disodium (R788) – for the Treatment of Rheumatoid Arthritis. Available from: http://www.astrazeneca.com/media/ latest-press-releases/rigel-licensing?itemId=8539858 [Last accessed 02 July 2010]
   Google Scholar
• Leung BP, Culshaw S, Gracie JA, A role for IL-18 in neutrophil activation. J Immunol 2001;167(5):2879-86
   PubMed Web of Science ®Google Scholar
• Emery P, Kvien TK, Combe B, [LB0001] very early (<4 months) treatment with combination etanercept (ETN) and methotraxate (MTX) produces significantly better remision rates: results from the COMET study. Ann Rheum Dis 2010;69(Suppl 3):57
   Google Scholar
• Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2(6):346-57
   PubMed Web of Science ®Google Scholar
• Delavallee L, Semerano L, Assier E, Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11(6):R195
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Interleukin-6–a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S11-15
   PubMedGoogle Scholar
• Yanaba K, Bouaziz JD, Matsushita T, B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284-99
   PubMed Web of Science ®Google Scholar
• St Clair EW. Novel targeted therapies for autoimmunity. Curr Opin Immunol 2009;21(6):648-57
   PubMed Web of Science ®Google Scholar
• European Medicines Agency information on abatacept. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000701/human_med_000958.jsp& murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124& jsenabled=true [Last accessed 02 October 2010]
   Google Scholar
• Genant HK, Peterfy CG, Westhovens R, Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-9
   PubMed Web of Science ®Google Scholar
• Westhovens R, Robles M, Nayiager S, Wollenhaupt J, Disease remission is achieved within two years in over half of methotrexate naive patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE Trial [abstract]. Arthritis Rheum 2009;60(Suppl 10):638
   Google Scholar
• Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS). Available from: http://clinicaltrials.gov/ct2/show/NCT00774852?term=ACCESS&rank=10 [Last accessed 02 July 2010]
   Google Scholar
• Singh JA, Christensen R, Wells GA, Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848
   Google Scholar
• Hansel TT, Kropshofer H, Singer T, The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325-38
   PubMed Web of Science ®Google Scholar
• Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009;82:25-32
   PubMedGoogle Scholar
• Platanias LC. Mechanisms of type I and type II interferon mediated signalling. Nat Rev Immunol 2005;5(5):375-86
   PubMed Web of Science ®Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA, Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301(1):5-8
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25(4):401-6
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25(3):383-92
   PubMed Web of Science ®Google Scholar
• Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18(6):676-82
   PubMed Web of Science ®Google Scholar
• Mathian A, Weinberg A, Gallegos M, IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005;174(5):2499-506
   PubMed Web of Science ®Google Scholar
• Santiago-Raber ML, Baccala R, Haraldsson KM, Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197(6):777-88
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197(6):711-23
   PubMed Web of Science ®Google Scholar
• Feng X, Wu H, Grossman JM, Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54(9):2951-62
   PubMed Web of Science ®Google Scholar
• Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43(7):1431-42
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001;22(8):427-31
   PubMed Web of Science ®Google Scholar
• Guiducci C, Gong M, Xu Z, TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010;465:937-41
   PubMed Web of Science ®Google Scholar
• Yao Y, Richman L, Higgs BW, Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60(6):1785-96
   PubMed Web of Science ®Google Scholar
• McBride JM, Wallace DJ, Yao Z, Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE. Arthritis Rheum 2009;60:S775-6
   Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Ann Rev Immunol 1998;16:293-322
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. Pharmaceuticals 2010;3:1446-55
   Google Scholar
• Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24(4):513-26
   PubMed Web of Science ®Google Scholar
• Kremer JM, Cohen S, Wilkinson B, Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA). ACR, Philadelphia; 17 – 21 October 2009. p. 1925
   Google Scholar
• Fleischmann RM, Genovese MC, Gruben D, Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA). ACR, Philadelphia; 17 – 21 October 2009. p. 1924
   Google Scholar
• Long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Available from: http://clinicaltrials.gov/ct2/ show/NCT00413699 [Last accessed 02 July 2010]
   Google Scholar
• Long-term, open-label study of CP-690,550 for treatment of rheumatoid arthritis in Japan. Available from: http://clinicaltrials.gov/ct2/show/NCT00661661 [Last accessed 05 September 2010]
   Google Scholar
• Hennessy EJ, Parker AE, O'Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010;9(4):293-307
   PubMed Web of Science ®Google Scholar
• Gilliet M, Cao W, Liu Y-J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594-606
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416(6881):603-7
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9
   PubMed Web of Science ®Google Scholar
• Lipford G, Forsbach A, Zepp C, Selective toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases [abstract 1596]. ACR 6 – 11 November 2009; Boston, MA
   Google Scholar
• Barrat FJ, Meeker T, Gregorio J, Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Chan JH, Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37(12):3582-6
   PubMed Web of Science ®Google Scholar
• DV1179. Available from: http:// www.dynavax.com/autoimmunity.html [Last accessed 13 July 2010]
   Google Scholar
• IMO-3100. Available from: http://www.iderapharma.com/development/imo-3100.php [Last accessed 02 July 2010]
   Google Scholar
• Zhu F-G, Dong Y, Kandimalla ER, Agrawal S. Studies of combination of IMO-3100, an antagonist of TLR7 and TLR9, and etanercept, a TNF- inhibitor, in a mouse model of collagen-induced arthritis (CIA). Arthritis Rheum 2009;60(Suppl 10):659
   Google Scholar
• Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009;11(5):247
   PubMed Web of Science ®Google Scholar
• Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010;22(3):307-15
   PubMed Web of Science ®Google Scholar
• Sousa E, Isenberg D. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. Best Pract Res Clin Rheumatol 2009;23:563-74
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik J, Sanz I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010;20:1-10
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. (EXPLORER). Arthritis Rheum 2010;62(1):222-33
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). Rituxan warning. FDA Consum 2007;41:3
   Google Scholar
• Ocrelizumab. Available from: http://www.roche.com/media/media_releases/med-cor-2010-03-08.htm [Last accessed 13 July 2010]
   Google Scholar
• Carnahan J, Wang P, Kendall R, Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982s-90s
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8:R129
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
   PubMed Web of Science ®Google Scholar
• Cardarelli PM, Blanset D, Rao-Naik C, A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for treatment of autoimmune diseases [abstract]. Arthritis Rheum 2009;60(10):692
   Google Scholar
• Nagorsen D, Bargou R, Ruttinger D, Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50:886
   PubMed Web of Science ®Google Scholar
• Vallera DA, Chen H, Sicheneder AR, Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33(9):1233-42
   PubMed Web of Science ®Google Scholar
• Belnoue E, Pihlgren M, McGaha TL, APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111:2755-64
   PubMed Web of Science ®Google Scholar
• Litinskiy MB, Nardelli B, Hilbert DM, DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9
   PubMed Web of Science ®Google Scholar
• Treml LS, Carlesso G, Hoek KL, TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007;178(12):7531-9
   PubMed Web of Science ®Google Scholar
• Groom JR, Fletcher CA, Walters SN, BAFF and MyD88 signals promote a lupus like disease independent of T cells. J Exp Med 2007;204:1959-71
   PubMed Web of Science ®Google Scholar
• Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006;18:284-9
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning JL. BAFF and APRIL: a tutorial on В cell survival. Annu Rev Immunol 2003;21:231-64
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008;223:156-7
   PubMed Web of Science ®Google Scholar
• Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005;8:243-65
   PubMedGoogle Scholar
• Furie R, Stohl W, Ginzler EM, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10(5):R109
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1168-78
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
   PubMed Web of Science ®Google Scholar
• Mok CC. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2010;15(1):53-70
   PubMed Web of Science ®Google Scholar
• Navarra S, Guzman R, Gallacher A, Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. ACR, Philadelphia; 17 – 21 October 2009. p. LB1
   Google Scholar
• Chatham W, Furie R, Petri M, Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 3 years of therapy. ACR, San Francisco; 25 – 29 October 2008. p. 1094
   Google Scholar
• Genovese MC. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). ACR, Philadelphia; 17 – 21 October 2009. p. 1923
   Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56(12):4142-50
   PubMed Web of Science ®Google Scholar
• Pena-Rossi C, Nasonov E, Stanislav M, An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009;18(6):547-55
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C, Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58(1):61-72
   PubMed Web of Science ®Google Scholar
• Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010;99:524-38
   PubMed Web of Science ®Google Scholar
• Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22(3):330-5
   PubMed Web of Science ®Google Scholar
• Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010, doi:10.1016/j.drudis.2010.05.001
   Google Scholar
• Weinblatt M, Kavanaugh A, Genovese M, An oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis. NEJM 2010;363(14):1303-12
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kavanaugh A, Weinblatt ME, An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum 2010: DOI 10.1002/art.30114
   Google Scholar
• Song IH, Gold R, Straub RH, New glucocorticoids on the horizon: repress, don't activate! J Rheumatol 2005;32(7):1199-1207
   Web of Science ®Google Scholar
• Stock T, Fleishaker D, Mukherjee A, Evaluation of safety, pharmacokinetics and pharmacodynamics of a selective glucocorticoid receptor modulator (SGRM) in healthy volunteers. ACR, Philadelphia; 17 – 21 October 2009. p. 420
   Google Scholar
• Gerlag DM, Haringman JJ, Smeets TJ, Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50(12):3783-91
   PubMed Web of Science ®Google Scholar
• Campbell IK, Rich MJ, Bischof RJ, Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998;161(7):3639-44
   PubMed Web of Science ®Google Scholar
• Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol 2000;68(1):144-50
   PubMed Web of Science ®Google Scholar
• Lawlor KE, Campbell IK, Metcalf D, Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci USA 2004;101:11398-403
   PubMed Web of Science ®Google Scholar
• Cornish AL, Campbell IK, McKenzie BS, G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):554-9
   PubMed Web of Science ®Google Scholar
• Huston A, Lyman GH. Agents under investigation for the treatment and prevention of neutropenia. Expert Opin Investig Drugs 2007;16(11):1831-40
   PubMed Web of Science ®Google Scholar
• Hayat SQ, Hearth-Holmes M, Wolf RE. Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 1995;14(2):211-12
   PubMed Web of Science ®Google Scholar
• Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989;74(8):2769-70
   PubMed Web of Science ®Google Scholar
• de Vries EG, Willemse PH, Biesma B, Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991;338(8765):517-18
   PubMed Web of Science ®Google Scholar
• Burmester GR, Wagner F, Feist E, Cam-3001; a novel human monoclonal antibody against GM-CSFR, in subjects with rheumatoid arthritis (RA): results of a PhI Study. ACR, Philadelphia; 17 – 21 October 2009. p. 1926
   Google Scholar
• Mackay F, Majeau GR, Lawton P, Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Eur J Immunol 1997;27(8):2033-42
   PubMed Web of Science ®Google Scholar
• Fava RA, Notidis E, Hunt J, A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003;171(1):115-26
   PubMed Web of Science ®Google Scholar
• Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 2008;223:202-20
   PubMed Web of Science ®Google Scholar
• Isaacs D, Genovese MC, Emery P, Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) – preliminary results of the phase 2b study in the DMARD-IR population. ACR, Philadelphia; 17 – 21 October 2009. p. 416
   Google Scholar
• Chiang EY, Kolumam GA, Yu X, Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
   PubMed Web of Science ®Google Scholar
• Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol 2009;16(4):274-9
   PubMed Web of Science ®Google Scholar
• Koenders MI, van den Berg WB. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol 2010;159(2):131-6
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010;28:445-89
   PubMed Web of Science ®Google Scholar
• Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171(11):6173-7
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, Oppers-Walgreen B, Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50(2):650-9
   PubMed Web of Science ®Google Scholar
• Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46(3):802-5
   PubMed Web of Science ®Google Scholar
• Nakae S, Saijo S, Horai R, IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100(10):5986-90
   PubMed Web of Science ®Google Scholar
• Hirota K, Hashimoto M, Yoshitomi H, T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007;204(1):41-7
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):549-53
   PubMed Web of Science ®Google Scholar
• Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129(3):311-21
   PubMed Web of Science ®Google Scholar
• Goldberg M, Nadiv O, Luknar-Gabor N, Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009;46(8-9):1854-9
   PubMed Web of Science ®Google Scholar
• Guilloteau K, Paris I, Pedretti N, Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010;184:5263-70
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009;157(2):209-15
   PubMed Web of Science ®Google Scholar
• Brucklacher-Waldert V, Stuerner K, Kolster M, Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009;132(Pt 12):3329-41
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J, Genovese MC, Roberson SA, Van den Bosch F. Safety, tolerability and evidence of efficacy of intravenous LY2439821 in patients with rheumatoid arthritis receiving background oral DMARDS [abstract OP-0160]. EULAR 2009; Copenhagan, Denmark
   Google Scholar
• Durez P, Chindalore V, Wittmer B, AIN457, an anti-IL17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial [abstract LB0002]. EULAR 2009; Copenhagan, Denmark
   Google Scholar
• Mus AM, Cornelissen F, Asmawidjaja PS, Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 2010;62(4):1043-50
   PubMed Web of Science ®Google Scholar
• Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007;104(29):12099-104
   PubMed Web of Science ®Google Scholar
• Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176(3):1908-15
   PubMed Web of Science ®Google Scholar
• Hedrick MN, Lonsdorf AS, Shirakawa AK, CCR6 is required for IL-23–induced psoriasis-like inflammation in mice. J Clin Invest 2009;119(8):2317-29
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, ; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-1674
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, ; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84
   PubMed Web of Science ®Google Scholar
• Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10(4):587-604
   PubMed Web of Science ®Google Scholar
• Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010;160(4):810-20
   PubMed Web of Science ®Google Scholar
• Burakoff R, Barish CF, Riff D, A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12(7):558-65
   PubMed Web of Science ®Google Scholar